Mashayekhi Kambis, Büttner Heinz Joachim
Klinik für Kardiologie und Angiologie II, Universitäts-Herzzentrum Freiburg - Bad Krozingen, Deutschland.
Ther Umsch. 2021 Feb;78(1):23-30. doi: 10.1024/0040-5930/a001233.
Recanalisation of chronic total coronary occlusions - what is the evidence and which patients will benefit? Continuous improvement of recanalisation techniques and newer device technologies significantly improved the success of revascularisation in percutaneous coronary intervention (PCI) of chronic total occluded coronary arteries (CTO) in the past few years. The best documented clinical benefit of CTO-PCI is symptom control, based on a reduction of myocardial ischemia. In contrast, there is still an ongoing controversial debate regarding the prognostic benefit of successful CTO-PCI shown in several observational studies. Therefore, the indication for CTO-PCI is primarily based on patients' symptoms and the extent of myocardial ischemia. The risk / benefit ratio for the individual patient has to be estimated from technical complexity of the CTO lesion, the extent of the coronary artery disease and the ventricular function. Recanalisation strategy should be escalating, as most of the CTOs can be successfully recanalised with standard antegrade recanalisation techniques. With the implementation of retrograde CTO techniques, the likelihood for recanalisation success is very high (> 90 %) even in complex anatomies, combined with low complication rates in specialised centers. According to the operator's expertise a complete catheter-based revascularisation can be achieved nowadays even in patients with CTO and coronary multi-vessel disease.
慢性完全性冠状动脉闭塞病变的再通——证据是什么,哪些患者将从中获益?在过去几年中,再通技术和新型器械技术的不断改进显著提高了慢性完全闭塞冠状动脉(CTO)经皮冠状动脉介入治疗(PCI)中血管重建的成功率。CTO-PCI最确凿的临床益处是基于心肌缺血减少的症状控制。相比之下,几项观察性研究中显示的成功CTO-PCI的预后益处仍存在争议。因此,CTO-PCI的适应证主要基于患者的症状和心肌缺血程度。必须根据CTO病变的技术复杂性、冠状动脉疾病的范围和心室功能来评估个体患者的风险/获益比。再通策略应逐步升级,因为大多数CTO可以通过标准的顺向再通技术成功再通。随着逆向CTO技术的应用,即使在复杂解剖结构中,再通成功的可能性也非常高(>90%),并且在专业中心并发症发生率较低。根据术者的专业技能,如今即使是患有CTO和冠状动脉多支病变的患者也能实现完全基于导管的血管重建。